Futao Meng

218 Jixi Road
Hefei, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

1,2,3,6-Tetragalloylglucose inhibits hnRNPA2B1/TRAIL Axis to attenuate apoptosis and barrier dysfunction in intestinal epithelial cells: A potential therapeutic avenue for IBD.

1,2,3,6-Tetragalloylglucose inhibits hnRNPA2B1/TRAIL Axis to attenuate apoptosis and barrier dysfunction in intestinal epithelial cells: A potential therapeutic avenue for IBD.

Journal: Cellular signalling

Published: October 25, 2025

Advanced optical methods and strategies for extracellular vesicles characterization and dynamic studies.

Advanced optical methods and strategies for extracellular vesicles characterization and dynamic studies.

Journal: Chemistry and physics of lipids

Published: July 07, 2025

Correction: NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism.

Correction: NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism.

Journal: Molecular medicine (Cambridge, Mass.)

Published: May 10, 2025

IGF2BP2 alleviates ulcerative colitis by inhibiting MEK1/2 and ERK1/2 signaling pathways in intestinal epithelial cells via m6A-dependent stabilization of LGI4 mRNA.

IGF2BP2 alleviates ulcerative colitis by inhibiting MEK1/2 and ERK1/2 signaling pathways in intestinal epithelial cells via m6A-dependent stabilization of LGI4 mRNA.

Journal: International immunopharmacology

Published: May 04, 2025

NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism.

NEK8 promotes the progression of gastric cancer by reprogramming asparagine metabolism.

Journal: Molecular medicine (Cambridge, Mass.)

Published: September 14, 2024

Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Journal: Scientific reports

Published: November 28, 2023

Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.

Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.

Journal: Cancer gene therapy

Published: February 20, 2023

Activated Pancreatic Stellate Cells Enhance the Warburg Effect to Cause the Malignant Development in Chronic Pancreatitis.

Activated Pancreatic Stellate Cells Enhance the Warburg Effect to Cause the Malignant Development in Chronic Pancreatitis.

Journal: Frontiers in oncology

Published: May 25, 2021

Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment.

Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment.

Journal: Cellular & molecular immunology

Published: February 06, 2018

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.

Journal: Frontiers in pharmacology

Published: January 12, 2018

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.

Journal: Scientific reports

Published: December 06, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026